Jean-louis L. Legoux - Publications

How to Balance Prognostic Factors in Controlled Phase II Trials: Stratified Permuted Block Randomization or Minimization? An Analysis of Clinical Trials in Digestive Oncology.

Journal: Current oncology (Toronto, Ont.)

Published: May 14, 2024

First-Line LV5FU2 with or without Aflibercept in Patients with Non-Resectable Metastatic Colorectal Cancer: A Randomized Phase II Trial (PRODIGE 25-FFCD-FOLFA).

Journal: Cancers

Published: March 27, 2024

Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer.

Journal: The oncologist

Published: December 02, 2023

Adjuvant chemotherapy benefit according to T and N stage in small bowel adenocarcinoma: a large retrospective multicenter study.

Journal: JNCI cancer spectrum

Published: May 18, 2023

Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 24, 2022

Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: May 04, 2021

Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 15, 2021

Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial.

Journal: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

Published: December 17, 2020

Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational study.

Journal: Clinics and research in hepatology and gastroenterology

Published: December 03, 2020

Narrow-band imaging versus Lugol chromoendoscopy for esophageal squamous cell cancer screening in normal endoscopic practice: randomized controlled trial.

Journal: Endoscopy

Published: July 22, 2020

Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.

Journal: International journal of cancer

Published: July 10, 2020

Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: May 15, 2020